Bristol-Myers Squibb (NYSE:BMY – Get Free Report) was downgraded by analysts at Citigroup from a “buy” rating to a “neutral” rating in a note issued to investors on Friday, FinViz reports. They presently have a $55.00 target price on the biopharmaceutical company’s stock, down from their prior target price of $75.00. Citigroup’s target price would indicate a potential upside of 3.93% from the stock’s current price.
Several other equities research analysts also recently issued reports on BMY. UBS Group upped their price target on Bristol-Myers Squibb from $50.00 to $54.00 and gave the stock a “neutral” rating in a report on Wednesday, October 9th. Barclays upped their price objective on Bristol-Myers Squibb from $42.00 to $43.00 and gave the company an “underweight” rating in a research note on Monday, October 7th. TD Cowen upped their price objective on Bristol-Myers Squibb from $53.00 to $59.00 and gave the company a “hold” rating in a research note on Monday, October 7th. StockNews.com upgraded Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Monday, July 29th. Finally, Jefferies Financial Group upped their price objective on Bristol-Myers Squibb from $49.00 to $51.00 and gave the company a “hold” rating in a research note on Wednesday, August 28th. Two research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $53.31.
Read Our Latest Stock Report on Bristol-Myers Squibb
Bristol-Myers Squibb Trading Down 0.3 %
Bristol-Myers Squibb (NYSE:BMY – Get Free Report) last announced its quarterly earnings results on Friday, July 26th. The biopharmaceutical company reported $2.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.64 by $0.43. Bristol-Myers Squibb had a positive return on equity of 12.51% and a negative net margin of 14.06%. The business had revenue of $12.20 billion during the quarter, compared to the consensus estimate of $11.54 billion. During the same quarter in the prior year, the company posted $1.75 earnings per share. Bristol-Myers Squibb’s revenue was up 8.7% compared to the same quarter last year. On average, sell-side analysts anticipate that Bristol-Myers Squibb will post 0.77 earnings per share for the current fiscal year.
Institutional Trading of Bristol-Myers Squibb
Institutional investors have recently added to or reduced their stakes in the stock. ESL Trust Services LLC purchased a new stake in Bristol-Myers Squibb during the 1st quarter worth about $27,000. ORG Wealth Partners LLC purchased a new stake in Bristol-Myers Squibb during the 3rd quarter worth about $34,000. LGT Financial Advisors LLC lifted its holdings in Bristol-Myers Squibb by 42.7% during the 2nd quarter. LGT Financial Advisors LLC now owns 759 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 227 shares in the last quarter. Redmont Wealth Advisors LLC purchased a new stake in shares of Bristol-Myers Squibb in the 1st quarter valued at about $47,000. Finally, MFA Wealth Advisors LLC purchased a new stake in shares of Bristol-Myers Squibb in the 2nd quarter valued at about $39,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Recommended Stories
- Five stocks we like better than Bristol-Myers Squibb
- Which Wall Street Analysts are the Most Accurate?
- The Downtrend in UPS Stock Isn’t Over Yet
- What Makes a Stock a Good Dividend Stock?
- Maximize Portfolio Income with These 3 Dividend ETFs
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Talen Energy: A Nuclear Power Stock That Can Keep Winning
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.